RecruitingPhase 3

Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

United States510 participantsStarted 2026-02-17

Plain-language summary

Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of Ocular Hypertension or Open-Angle Glaucoma in the study eye Exclusion Criteria: * Prior incisional glaucoma surgery in the study eye * Prior argon laser trabeculoplasty (ALT) in the study eye * Prior minimally invasive glaucoma (MIGS) surgery in the study eye

What they're measuring

Intraocular pressure (IOP)

Timeframe: 3 months

Trial details

NCT IDNCT07495852

SponsorGlaukos Corporation

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2028-06

Contact for this trial

Study Director

949-739-8749 ClinicalResearch@glaukos.com

View on ClinicalTrials.gov More Glaucoma trials